Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v3.3.0.814
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Operating Activities:    
Net loss $ (15,077) $ (20,559)
Adjustments to reconcile net loss to net cash used in operating activities:    
(Gain) loss on warrants (166) (2,768)
Warrant Issue Costs   531
Depreciation 178 165
Stock-based compensation [note 5 [c] and note 5 [d]] 1,940 2,968
Changes in operating assets and liabilities:    
Interest receivable 65 199
Amounts receivable 5,663 3,830
Prepaid expenses and other assets 1,554 3,646
Accounts payable 1,707 1,423
Accrued liabilities other (2,052) 229
Accrued clinical liabilities (3,494) 1,154
Accrued compensation 277 (596)
Restricted cash 29 63
Excess lease liability [note 6] (194) (582)
Lease obligation 113 (67)
Deferred collaboration revenue [Note 3] 11,041  
Net cash (used in) provided by operating activities 1,584 (10,364)
Financing Activities:    
Proceeds from the exercise of stock options   30
Proceeds received in advance related to the July 2014 registered offering   2,860
Proceeds from issuance of common shares, net of issuance costs   22,372
Proceeds from purchase agreement with Lincoln Park Capital, net of issuance costs [note 5 [b]] 17,629  
Taxes paid related to net share settlement of equity awards (52) (28)
Net cash provided by financing activities 17,577 25,234
Investing Activities:    
Purchase of investments (22,942) (5,279)
Proceeds from sale of investments 1,003  
Proceeds from maturities of investments 17,659 24,846
Purchase of property and equipment (301) (80)
Net cash (used in) provided by investing activities (4,581) 19,487
Net increase in cash and cash equivalents 14,580 34,357
Cash and cash equivalents at beginning of period 27,897 14,593
Cash and cash equivalents at end of period 42,477 $ 48,950
Non cash financing activities    
Issued common stock in consideration for the purchase agreement with Lincoln Park Capital [note 5] $ 254